Nexalin Technology, Inc. (NASDAQ: NXL) experienced a remarkable trading session on Friday, with its stock price skyrocketing nearly 50%. However, the momentum did not stop there. In afterhours trading, its stock soared an additional 40%, driven by a significant volume surge of nearly 58 million shares, a stark contrast to its average daily volume of less than 2 million shares.
Patent Announcement Ignites Nexalin Surge
The dramatic boost in Nexalin’s stock price was catalyzed by the company’s announcement of a key patent award. On Thursday, the United States Patent and Trademark Office (USPTO) granted Nexalin U.S. Patent No 12,011,591.
This patent pertains to the company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for treating Alzheimer’s and other dementia-related brain diseases. This new technology is part of Nexalin’s Gen-2 and Gen-3 devices, which utilize a proprietary frequency-based waveform designed to treat patients effectively and painlessly.
Nexalin’s Innovative Neurostimulation Solutions
Nexalin Technology is at the forefront of developing non-invasive neurostimulation products aimed at addressing the global mental health crisis. The company’s devices are designed to provide relief for various mental health issues, including depression, anxiety, insomnia, addiction, and PTSD, without any adverse side effects. The recently approved Gen-2 15 milliamp (mA) neurostimulation device in China for treating insomnia and depression exemplifies the company’s commitment to innovative solutions.
NXL’s neurostimulation devices are believed to penetrate deep brain structures. These are associated with mental health disorders, providing enhanced patient responses. The DIFS® technology, integral to the new patent, represents a digital breakthrough in electrical waveforms, offering deep, undetectable brain stimulation through strategically placed electrodes on the cranium.
Conclusion
The afterhours surge in NXL stock reflects strong investor confidence and optimism fueled by the company’s recent patent achievement. With a robust pipeline of innovative neurostimulation products and significant market potential, NXL is well-positioned to revolutionize the treatment of Alzheimer’s and other mental health disorders.
Social media sentiment around the stock remains extremely bullish, indicating continued positive momentum for the company.